This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-07-2604v1 68/4/965    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by DiFeo, A. Articles by Narla, G. PubMed PubMed Citation Articles by DiFeo, A. Articles by Narla, G.

A Functional Role for KLF6-SV1 in Lung Adenocarcinoma Prognosis and Chemotherapy Response

Departments of ¹ Genetics and Genomic Sciences, ² Oncological Sciences, and ³ Medicine, the Mount Sinai School of Medicine, New York, New York; and ⁴ Department of Surgery, University of Michigan, Ann Arbor, Michigan

Requests for reprints: Goutham Narla, Mount Sinai School of Medicine, 1425 Madison Avenue, Room 14-22, New York, NY 10029. Phone: 212-659-9218; E-mail: Goutham.Narla@mssm.edu.

Key Words: oncogene • lung cancer • Krupppel like • KLF6 • chemotherapy

Kruppel-like factor 6 (KLF6) is a tumor suppressor gene that is functionally inactivated in human cancer by loss of heterozygosity, somatic mutation, decreased expression, and increased alternative splicing into an oncogenic splice variant, KLF6-SV1. Here we show that increased expression of KLF6-SV1 is associated with decreased survival in patients with lung adenocarcinoma. In addition, KLF6-SV1 is a novel antiapoptotic protein in lung cancer cell lines, and targeted reduction of KLF6-SV1 using siRNA induces apoptosis both alone and in combination with the chemotherapeutic drug cisplatin. Together, these findings highlight a critical role for KLF6-SV1 in lung cancer, and show a potential novel therapeutic strategy for the treatment of lung cancer. [Cancer Res 2008;68(4):965–70]

This article has been cited by other articles:

				J. D. Fackenthal and L. A. Godley Aberrant RNA splicing and its functional consequences in cancer cells Disease Models and Mechanisms, July 1, 2008; 1(1): 37 - 42. [Abstract] [Full Text] [PDF]